OA11601A - Stabilized pharmaceutical composition in lyophilized form. - Google Patents

Stabilized pharmaceutical composition in lyophilized form. Download PDF

Info

Publication number: OA11601A
Authority: OA; OAPI
Prior art keywords: composition; stabilizer; compound; group; substituted
Prior art date: 1999-07-01

Application number

OA1200100048A

Other languages

English (en)

Inventor

Kasai Akihiro

Otomo Kazumi

Sawai Seiji

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-01

Filing date

2000-06-29

Publication date

2004-07-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-29 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

2004-07-30 Publication of OA11601A publication Critical patent/OA11601A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
150000001875 compounds Chemical class 0.000 claims abstract description 75
125000004122 cyclic group Chemical group 0.000 claims abstract description 29
229920001184 polypeptide Polymers 0.000 claims abstract description 27
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
239000003381 stabilizer Substances 0.000 claims abstract description 26
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 25
125000002252 acyl group Chemical group 0.000 claims abstract description 21
239000011780 sodium chloride Substances 0.000 claims abstract description 13
150000002016 disaccharides Chemical class 0.000 claims abstract description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
150000004676 glycans Chemical class 0.000 claims abstract description 7
229920001282 polysaccharide Polymers 0.000 claims abstract description 7
239000005017 polysaccharide Substances 0.000 claims abstract description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 58
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
239000000243 solution Substances 0.000 claims description 28
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 22
239000008101 lactose Substances 0.000 claims description 22
239000008213 purified water Substances 0.000 claims description 7
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
IXWNIYCPCRHGAE-DFZOHVKFSA-N alpha-D-GalNAc-(1->3)-D-Gal Chemical group CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O IXWNIYCPCRHGAE-DFZOHVKFSA-N 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 16
-1 heterocyclic carboxylic acids Chemical class 0.000 description 50
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 40
125000000623 heterocyclic group Chemical group 0.000 description 18
125000003545 alkoxy group Chemical group 0.000 description 14
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 13
125000004433 nitrogen atom Chemical group N* 0.000 description 12
125000003118 aryl group Chemical group 0.000 description 8
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
239000012535 impurity Substances 0.000 description 7
125000002911 monocyclic heterocycle group Chemical group 0.000 description 7
229910052717 sulfur Inorganic materials 0.000 description 7
125000004429 atom Chemical group 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
125000004193 piperazinyl group Chemical group 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
125000004434 sulfur atom Chemical group 0.000 description 5
239000002253 acid Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
125000001113 thiadiazolyl group Chemical group 0.000 description 4
241000228212 Aspergillus Species 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
239000011521 glass Substances 0.000 description 3
201000000317 pneumocystosis Diseases 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
241000223205 Coccidioides immitis Species 0.000 description 2
241001527609 Cryptococcus Species 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
241001480035 Epidermophyton Species 0.000 description 2
241000233866 Fungi Species 0.000 description 2
241000159512 Geotrichum Species 0.000 description 2
241000233870 Pneumocystis Species 0.000 description 2
241000235527 Rhizopus Species 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
208000002474 Tinea Diseases 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000000843 anti-fungal effect Effects 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
210000000621 bronchi Anatomy 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
239000003814 drug Substances 0.000 description 2
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006530 (C4-C6) alkyl group Chemical group 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
241000235389 Absidia Species 0.000 description 1
241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
241000228193 Aspergillus clavatus Species 0.000 description 1
241000228197 Aspergillus flavus Species 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
241000351920 Aspergillus nidulans Species 0.000 description 1
241001465318 Aspergillus terreus Species 0.000 description 1
229920002498 Beta-glucan Polymers 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
241000228405 Blastomyces dermatitidis Species 0.000 description 1
206010005098 Blastomycosis Diseases 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000222173 Candida parapsilosis Species 0.000 description 1
241000222178 Candida tropicalis Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008803 Chromoblastomycosis Diseases 0.000 description 1
208000015116 Chromomycosis Diseases 0.000 description 1
241000033335 Cladophialophora bantiana Species 0.000 description 1
241000222290 Cladosporium Species 0.000 description 1
241000223203 Coccidioides Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
241000235555 Cunninghamella Species 0.000 description 1
241000235556 Cunninghamella elegans Species 0.000 description 1
241000223233 Cutaneotrichosporon cutaneum Species 0.000 description 1
241000235646 Cyberlindnera jadinii Species 0.000 description 1
206010012504 Dermatophytosis Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
241000223682 Exophiala Species 0.000 description 1
241000248325 Exophiala dermatitidis Species 0.000 description 1
241000308443 Exophiala spinifera Species 0.000 description 1
241000122862 Fonsecaea Species 0.000 description 1
241000122864 Fonsecaea pedrosoi Species 0.000 description 1
208000004770 Fusariosis Diseases 0.000 description 1
241000223218 Fusarium Species 0.000 description 1
241000427940 Fusarium solani Species 0.000 description 1
201000003950 Geotrichosis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
241000228402 Histoplasma Species 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
241000283986 Lepus Species 0.000 description 1
241000144128 Lichtheimia corymbifera Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000555676 Malassezia Species 0.000 description 1
241000555688 Malassezia furfur Species 0.000 description 1
241000235048 Meyerozyma guilliermondii Species 0.000 description 1
241001480037 Microsporum Species 0.000 description 1
241000893980 Microsporum canis Species 0.000 description 1
241001460074 Microsporum distortum Species 0.000 description 1
241000235395 Mucor Species 0.000 description 1
241000041810 Mycetoma Species 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical class CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
241000893976 Nannizzia gypsea Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001537205 Paracoccidioides Species 0.000 description 1
241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
206010033767 Paracoccidioides infections Diseases 0.000 description 1
201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
206010064458 Penicilliosis Diseases 0.000 description 1
241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
241000235645 Pichia kudriavzevii Species 0.000 description 1
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
241000223596 Pseudallescheria Species 0.000 description 1
241000593344 Rhizopus microsporus Species 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
241000223598 Scedosporium boydii Species 0.000 description 1
241000122799 Scopulariopsis Species 0.000 description 1
241001149962 Sporothrix Species 0.000 description 1
206010041736 Sporotrichosis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007712 Tinea Versicolor Diseases 0.000 description 1
206010056131 Tinea versicolour Diseases 0.000 description 1
241000223238 Trichophyton Species 0.000 description 1
241001045770 Trichophyton mentagrophytes Species 0.000 description 1
241000223229 Trichophyton rubrum Species 0.000 description 1
206010067409 Trichophytosis Diseases 0.000 description 1
241000223230 Trichosporon Species 0.000 description 1
241001634961 Trichosporon asahii Species 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
206010061418 Zygomycosis Diseases 0.000 description 1
241000222126 [Candida] glabrata Species 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
125000005116 aryl carbamoyl group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
208000032343 candida glabrata infection Diseases 0.000 description 1
229940055022 candida parapsilosis Drugs 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000001174 endocardium Anatomy 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
201000007524 mucormycosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
210000000537 nasal bone Anatomy 0.000 description 1
125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000009838 otomycosis Diseases 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
201000000508 pityriasis versicolor Diseases 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200100048A 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form. OA11601A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP18771399		1999-07-01

Publications (1)

Publication Number	Publication Date
OA11601A true OA11601A (en)	2004-07-30

Family

ID=16210881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100048A OA11601A (en)	1999-07-01	2000-06-29	Stabilized pharmaceutical composition in lyophilized form.

Country Status (28)

Country	Link
US (2)	US6774104B1 (de)
EP (1)	EP1107777B1 (de)
JP (2)	JP3381722B2 (de)
KR (1)	KR100454784B1 (de)
CN (2)	CN100352495C (de)
AR (1)	AR024634A1 (de)
AT (1)	ATE280583T1 (de)
AU (1)	AU752265B2 (de)
BR (2)	BR0006823A (de)
CA (1)	CA2341568C (de)
CZ (1)	CZ295720B6 (de)
DE (1)	DE60015279T2 (de)
ES (1)	ES2225161T3 (de)
HK (1)	HK1040057B (de)
HU (1)	HU229089B1 (de)
ID (1)	ID29468A (de)
IL (2)	IL141455A0 (de)
MX (1)	MXPA01000601A (de)
NO (1)	NO330353B1 (de)
NZ (1)	NZ510290A (de)
OA (1)	OA11601A (de)
PL (1)	PL200141B1 (de)
PT (1)	PT1107777E (de)
RU (1)	RU2251411C2 (de)
TR (1)	TR200100609T1 (de)
TW (1)	TWI233805B (de)
WO (1)	WO2001002002A1 (de)
ZA (1)	ZA200101589B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI233805B (en) *	1999-07-01	2005-06-11	Fujisawa Pharmaceutical Co	Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) *	2002-05-16	2003-11-17	Novuspharma Spa	Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US8877168B1 (en)	2002-07-31	2014-11-04	Senju Pharmaceuticals Co., Ltd.	Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8784789B2 (en)	2002-07-31	2014-07-22	Senju Pharmaceutical Co., Ltd.	Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US7119061B2 (en) *	2002-11-18	2006-10-10	Vicuron Pharmaceuticals, Inc.	Dalbavancin compositions for treatment of bacterial infections
AU2003294262B2 (en) *	2002-11-18	2007-08-23	Vicuron Pharmaceuticals Inc.	Methods of administering dalbavancin for treatment of bacterial infections
US20060074014A1 (en) *	2002-11-18	2006-04-06	Vicuron Pharmaceuticals Inc.	Dalbavancin compositions for treatment of bacterial infections
JPWO2005084679A1 (ja) *	2004-03-04	2007-11-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法
JP2007538046A (ja) *	2004-05-19	2007-12-27	ノイロサーチアクティーゼルスカブ	新規なアザビシクロアリール誘導体
KR20070109985A (ko) *	2004-11-22	2007-11-15	아나디스 리미티드	생물활성 조성물
KR101307999B1 (ko)	2004-12-01	2013-09-12	니폰 조키 세야쿠 가부시키가이샤	건조물 및 그 제조방법
CN101228442B (zh) *	2005-07-20	2013-03-27	协和梅迪克斯株式会社	生物样品中肽的稳定方法
CN1962852B (zh) *	2006-11-27	2011-11-09	西北农林科技大学	红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614491B (zh)	2011-01-31	2014-04-16	上海天伟生物制药有限公司	一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
CN102614492B (zh) *	2011-01-31	2013-12-11	上海天伟生物制药有限公司	一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
AP2014008084A0 (en) *	2012-05-22	2014-11-30	Paion Uk Ltd	Compositions comprising shortacting benzodiazepines
US9872906B2 (en)	2013-03-15	2018-01-23	Merck Sharp & Dohme Corp.	Ceftolozane antibiotic compositions
PE20160048A1 (es)	2013-03-15	2016-02-12	Merck Sharp & Dohme	Composiciones antibioticas de ceftolozano
US20140274996A1 (en)	2013-03-15	2014-09-18	Cubist Pharmaceuticals, Inc.	Tazobactam and ceftolozane antibiotic compositions
CN103330933B (zh) *	2013-04-26	2015-08-05	江苏豪森药业股份有限公司	含有米卡芬净或其盐的药物组合物
CN103330932B (zh) *	2013-04-26	2015-12-23	江苏豪森药业股份有限公司	一种米卡芬净或其盐的药物组合物
PL3003298T3 (pl) *	2013-06-05	2024-07-15	The University Of British Columbia	Związki antyfibrogenne, sposoby ich zastosowania
WO2015035376A2 (en)	2013-09-09	2015-03-12	Calixa Therapeutics, Inc.	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en)	2013-09-27	2014-12-09	Calixa Therapeutics, Inc.	Solid forms of ceftolozane
KR101611349B1 (ko)	2014-04-14	2016-04-12	신우철	안정성이 개선된 밀크씨슬 엑스의 제형
EP3150621A4 (de) *	2014-05-29	2017-12-27	Shanghai Techwell Biopharmaceutical Co., Ltd	Zusammensetzung einer cyclischen peptidverbindung, herstellungsverfahren dafür und verwendungen davon
BR112017010445B8 (pt) *	2014-12-05	2024-02-27	Meiji Seika Pharma Co Ltd	Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
EP3240529B1 (de) *	2014-12-31	2022-02-02	Galenicum Health S.L.U.	Stabile pharmazeutische zusammensetzungen mit micafungin
ES2694561T3 (es)	2015-02-23	2018-12-21	Selectchemie Ag	Composición de anidulafungina
PT3554474T (pt)	2016-12-16	2024-02-12	Baxter Healthcare Sa	Composições de micafungina
WO2019005829A1 (en) *	2017-06-26	2019-01-03	Wayne State University	METHODS AND COMPOSITIONS RELATING TO CANCER DEPENDENT ON HORMONE RECEPTORS
RU2666148C1 (ru) *	2017-10-05	2018-09-06	Общество с ограниченной ответственностью "Новые Антибиотики"	Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (de)	2017-11-17	2019-05-22	Cadila Healthcare Limited	Stabile pharmazeutische injizierbare zusammensetzungen von micafungin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03193735A (ja)	1989-12-22	1991-08-23	Shionogi & Co Ltd	グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja)	1990-02-15	1991-10-28	Toyo Jozo Co Ltd	ニューモシスチス・カリニ肺炎治療剤
IL98506A (en) *	1990-06-18	1996-09-12	Fujisawa Pharmaceutical Co	Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
JP3193735B2 (ja)	1991-07-24	2001-07-30	株式会社リコー	カラー画像形成装置の搬送装置
RU2095081C1 (ru) *	1991-12-13	1997-11-10	Акционерное общество "Биофа"	Фармацевтическая композиция антивирусного действия
JPH0651641A (ja)	1992-07-30	1994-02-25	Olympus Optical Co Ltd	湿式現像装置
JPH06172204A (ja) *	1992-12-09	1994-06-21	Asahi Chem Ind Co Ltd	アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja)	1993-02-25	2001-12-25	ソニー株式会社	偏平型陰極線管の画像歪補正装置
US6268338B1 (en) *	1993-04-30	2001-07-31	Merck & Co., Inc.	Cyclohexapeptidyl amine compounds
AU681119B2 (en) *	1993-05-17	1997-08-21	Fujisawa Pharmaceutical Co., Ltd.	New polypeptide compound and a process for preparation thereof
JP2897427B2 (ja) *	1994-10-07	1999-05-31	藤沢薬品工業株式会社	抗微生物活性を有する環状ヘキサペプチド化合物
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation
US6245349B1 (en) *	1996-02-23	2001-06-12	éLAN CORPORATION PLC	Drug delivery compositions suitable for intravenous injection
EP1854877B1 (de) *	1996-03-08	2012-02-08	Astellas Pharma Inc.	Verfahren zur Deacylierung von zyklischen Lipopeptiden
PE63998A1 (es) *	1996-04-19	1998-10-30	Merck & Co Inc	Composiciones anti-fungosas
JPH09301997A (ja)	1996-05-17	1997-11-25	Yamanouchi Pharmaceut Co Ltd	新規環状ペプチド系化合物
FR2755857B1 (fr) *	1996-11-19	1998-12-24	Rhone Poulenc Rorer Sa	Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO371596A0 (en) *	1996-11-19	1996-12-12	Fujisawa Pharmaceutical Co., Ltd.	New compound
AUPO381496A0 (en) *	1996-11-25	1996-12-19	Fujisawa Pharmaceutical Co., Ltd.	New compound
JPH10279498A (ja) *	1997-04-07	1998-10-20	Nippon Shinyaku Co Ltd	慢性関節リウマチ治療剤
JP3544847B2 (ja) *	1998-01-16	2004-07-21	三菱電機株式会社	光学的情報再生方法および装置
JP2002538097A (ja) *	1999-03-03	2002-11-12	イーライリリーアンドカンパニー	薬学的経口ｅｃｂ処方物および組成物の作製方法
EP1582204B1 (de) *	1999-03-03	2013-09-25	Eli Lilly & Company	Echinocandin pharmazeutische Zusammensetzungen enthaltend Mizellen bildende Tenside
TWI233805B (en) *	1999-07-01	2005-06-11	Fujisawa Pharmaceutical Co	Stabilized pharmaceutical composition in lyophilized form as antifungal agent

2000
- 2000-06-28 TW TW089112754A patent/TWI233805B/zh not_active IP Right Cessation
- 2000-06-29 BR BR0006823-3A patent/BR0006823A/pt not_active IP Right Cessation
- 2000-06-29 WO PCT/JP2000/004381 patent/WO2001002002A1/en not_active Ceased
- 2000-06-29 KR KR10-2001-7002318A patent/KR100454784B1/ko not_active Expired - Lifetime
- 2000-06-29 NZ NZ510290A patent/NZ510290A/en not_active IP Right Cessation
- 2000-06-29 CN CNB2004100880760A patent/CN100352495C/zh not_active Expired - Lifetime
- 2000-06-29 IL IL14145500A patent/IL141455A0/xx active IP Right Grant
- 2000-06-29 US US09/786,125 patent/US6774104B1/en not_active Expired - Lifetime
- 2000-06-29 CZ CZ20011186A patent/CZ295720B6/cs not_active IP Right Cessation
- 2000-06-29 MX MXPA01000601A patent/MXPA01000601A/es active IP Right Grant
- 2000-06-29 ES ES00940916T patent/ES2225161T3/es not_active Expired - Lifetime
- 2000-06-29 RU RU2001108569/15A patent/RU2251411C2/ru active
- 2000-06-29 PT PT00940916T patent/PT1107777E/pt unknown
- 2000-06-29 HU HU0103740A patent/HU229089B1/hu unknown
- 2000-06-29 EP EP00940916A patent/EP1107777B1/de not_active Expired - Lifetime
- 2000-06-29 HK HK02101689.2A patent/HK1040057B/zh not_active IP Right Cessation
- 2000-06-29 BR BRPI0006823A patent/BRPI0006823B8/pt unknown
- 2000-06-29 DE DE60015279T patent/DE60015279T2/de not_active Expired - Lifetime
- 2000-06-29 JP JP2001507492A patent/JP3381722B2/ja not_active Expired - Lifetime
- 2000-06-29 OA OA1200100048A patent/OA11601A/en unknown
- 2000-06-29 TR TR2001/00609T patent/TR200100609T1/xx unknown
- 2000-06-29 ID IDW20010749A patent/ID29468A/id unknown
- 2000-06-29 PL PL346297A patent/PL200141B1/pl unknown
- 2000-06-29 CN CNB008012164A patent/CN1179748C/zh not_active Expired - Lifetime
- 2000-06-29 AU AU55722/00A patent/AU752265B2/en not_active Expired
- 2000-06-29 AT AT00940916T patent/ATE280583T1/de active
- 2000-06-29 CA CA2341568A patent/CA2341568C/en not_active Expired - Lifetime
- 2000-06-30 AR ARP000103372A patent/AR024634A1/es not_active Application Discontinuation
2001
- 2001-02-15 IL IL141455A patent/IL141455A/en not_active IP Right Cessation
- 2001-02-22 NO NO20010893A patent/NO330353B1/no not_active IP Right Cessation
- 2001-02-26 ZA ZA200101589A patent/ZA200101589B/en unknown
- 2001-10-10 JP JP2001312701A patent/JP4691866B2/ja not_active Expired - Lifetime
2004
- 2004-02-06 US US10/772,281 patent/US7112565B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2341568A1 (en)	2001-01-11
IL141455A0 (en)	2002-03-10
HK1080724A1 (zh)	2006-05-04
CN1179748C (zh)	2004-12-15
BRPI0006823B8 (pt)	2021-05-25
ATE280583T1 (de)	2004-11-15
WO2001002002A1 (en)	2001-01-11
RU2251411C2 (ru)	2005-05-10
PT1107777E (pt)	2005-01-31
TR200100609T1 (tr)	2001-07-23
DE60015279T2 (de)	2005-05-25
KR100454784B1 (ko)	2004-11-05
ES2225161T3 (es)	2005-03-16
CZ295720B6 (cs)	2005-10-12
TWI233805B (en)	2005-06-11
JP2002363097A (ja)	2002-12-18
HK1040057A1 (en)	2002-05-24
BRPI0006823B1 (pt)	2020-01-07
US6774104B1 (en)	2004-08-10
HK1040057B (zh)	2005-08-05
HUP0103740A2 (hu)	2002-02-28
US7112565B2 (en)	2006-09-26
US20040157769A1 (en)	2004-08-12
AR024634A1 (es)	2002-10-16
CN1315865A (zh)	2001-10-03
MXPA01000601A (es)	2002-04-08
NO20010893D0 (no)	2001-02-22
AU752265B2 (en)	2002-09-12
CA2341568C (en)	2011-10-25
BR0006823A (pt)	2001-06-05
ID29468A (id)	2001-08-30
DE60015279D1 (de)	2004-12-02
CN100352495C (zh)	2007-12-05
HU229089B1 (en)	2013-07-29
NZ510290A (en)	2003-07-25
KR20010072903A (ko)	2001-07-31
IL141455A (en)	2006-12-31
ZA200101589B (en)	2002-09-02
PL346297A1 (en)	2002-01-28
NO330353B1 (no)	2011-04-04
HUP0103740A3 (en)	2002-08-28
CN1636591A (zh)	2005-07-13
JP4691866B2 (ja)	2011-06-01
CZ20011186A3 (cs)	2001-09-12
JP3381722B2 (ja)	2003-03-04
EP1107777B1 (de)	2004-10-27
JP2003503462A (ja)	2003-01-28
NO20010893L (no)	2001-04-24
AU5572200A (en)	2001-01-22
PL200141B1 (pl)	2008-12-31
EP1107777A1 (de)	2001-06-20

Publication	Publication Date	Title
CA2341568C (en)	2011-10-25	Stabilized pharmaceutical composition in lyophilized form
AU2011304408B2 (en)	2015-01-15	Caspofungin composition
EP1502589B1 (de)	2006-05-31	Wässrige injizierbare Suspensionen für Tiere enthaltend Florfenicol
US7375081B2 (en)	2008-05-20	Therapeutic combination of a pneumocandin derivative and an antifungal agent
JP2014504615A (ja)	2014-02-24	エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物
US20040023858A1 (en)	2004-02-05	Antifungal combination therapy
US20030220237A1 (en)	2003-11-27	Pharmaceutical composition
WO2002053584A1 (en)	2002-07-11	Stabilized pharmaceutical composition in lyophilized form
JP2019135214A (ja)	2019-08-15	溶解時の消泡性に優れかつ安定な凍結乾燥組成物
US20050004014A1 (en)	2005-01-06	New compound
AU1663401A (en)	2001-08-09	New use
US20220040092A1 (en)	2022-02-10	Ready to use injectable formulations of Micafungin Sodium